Status:
RECRUITING
Unraveling the Impact of Thalidomide at Diverse Doses in Transfusion Dependent Beta Thalassemia
Lead Sponsor:
National Institute of Blood and Marrow Transplant (NIBMT), Pakistan
Conditions:
Fetal Hemoglobin
Thalassemia Major
Eligibility:
All Genders
8-35 years
Phase:
PHASE2
Brief Summary
The project "Unraveling the Impact of Thalidomide at Diverse Doses in Transfusion Dependent Beta Thalassemia" investigates the safety and efficacy of low-dose thalidomide in managing beta thalassemia,...
Detailed Description
Thalassemia is an inherited monogenic blood disorder caused by improper synthesis of the hemoglobin chain, inherited in an autosomal recessive pattern. Hemoglobin is essential for oxygen transport fro...
Eligibility Criteria
Inclusion
- Know case of beta thalassemia major/ intermediate ( transfusion dependent)
- willing to give informed consent
Exclusion
- Patients with comorbidities such as liver dysfunction
- Married patients
- Lactating mother
- H/O thrombosis and fits
Key Trial Info
Start Date :
April 22 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 22 2026
Estimated Enrollment :
54 Patients enrolled
Trial Details
Trial ID
NCT06490627
Start Date
April 22 2024
End Date
April 22 2026
Last Update
May 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Institute of blood disease and bone marrow transplant
Karachi, Sindh, Pakistan